Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Pharmaceutical Research

• Publication date

  2012-02-03

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s11095-012-0666-zPMID 22302521PMCID PMC3409642
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regioselective Glucuronidation of Flavonols by Six Human UGT1A Isoforms

  2011cited by this paper
• Molecular modeling used to evaluate CYP2C9-dependent metabolism: homology modeling, molecular dynamics and docking simulations.

  2011cited by this paper
• Characterization of Niflumic Acid as a Selective Inhibitor of Human Liver Microsomal UDP-Glucuronosyltransferase 1A9: Application to the Reaction Phenotyping of Acetaminophen Glucuronidation

  2011cited by this paper
• Three-Dimensional Quantitative Structure-Activity Relationship Studies on UGT1A9-Mediated 3-O-Glucuronidation of Natural Flavonols Using a Pharmacophore-Based Comparative Molecular Field Analysis Model

  2011cited by this paper
• First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

  2011cited by this paper
• The crystal structure of human UDP-glucuronosyltransferase 2B7 C-terminal end is the first mammalian UGT target to be revealed: the significance for human UGTs from both the 1A and 2B families

  2010cited by this paper
• How Many and Which Amino Acids Are Responsible for the Large Activity Differences between the Highly Homologous UDP-Glucuronosyltransferases (UGT) 1A9 and UGT1A10?

  2010cited by this paper
• Identification of the position of mono-O-glucuronide of flavones and flavonols by analyzing shift in online UV spectrum (lambdamax) generated from an online diode array detector.

  2010cited by this paper
• Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors

  2010cited by this paper
• The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro–in vivo extrapolation of drug clearance and drug-drug interaction potential

  2010cited by this paper
• Molecular modeling of cytochrome P450 and drug metabolism.

  2010cited by this paper
• A Molecular Model of the Human UDP-Glucuronosyltransferase 1A1, Its Membrane Orientation, and the Interactions between Different Parts of the Enzyme

  2010cited by this paper
• Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.

  2010cited by this paper
• Ligand orientation governs conjugation capacity of UDP-glucuronosyltransferase 1A1.

  2010cited by this paper
• Relative Importance of Intestinal and Hepatic Glucuronidation—Impact on the Prediction of Drug Clearance

  2009cited by this paper
• The Simcyp population-based ADME simulator.

  2009cited by this paper
• The Simcyp® Population-based ADME Simulator

  2009cited by this paper
• In silico and in vitro approaches to elucidate the thermal stability of human UDP-glucuronosyltransferase (UGT) 1A9.

  2009cited by this paper
• Functional Characterization of Low-Prevalence Missense Polymorphisms in the UDP-Glucuronosyltransferase 1A9 Gene The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material.

  2009cited by this paper
• Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes

  2009cited by this paper
• Structure and concentration changes affect characterization of UGT isoform-specific metabolism of isoflavones.

  2009cited by this paper
• Mutation analysis in UGT1A9 suggests a relationship between substrate and catalytic residues in UDP-glucuronosyltransferases.

  2008cited by this paper
• Improving early drug discovery through ADME modelling: an overview.

  2007cited by this paper
• Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7.

  2007cited by this paper
• Crystal structure of Medicago truncatula UGT85H2--insights into the structural basis of a multifunctional (iso)flavonoid glycosyltransferase.

  2007cited by this paper
• Structure of a flavonoid glucosyltransferase reveals the basis for plant natural product modification

  2006cited by this paper
• Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases.

  2005cited by this paper
• A comparative molecular field analysis-based approach to prediction of sulfotransferase catalytic specificity.

  2005cited by this paper
• KINETIC CHARACTERIZATION OF THE 1A SUBFAMILY OF RECOMBINANT HUMAN UDP-GLUCURONOSYLTRANSFERASES

  2005cited by this paper
• Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily.

  2005cited by this paper
• MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist.

  2005cited by this paper
• Crystal Structures of a Multifunctional Triterpene/Flavonoid Glycosyltransferase from Medicago truncatula

  2005cited by this paper
• GROMACS: Fast, flexible, and free

  2005cited by this paper
• Towards integrated ADME prediction: past, present and future directions for modelling metabolism by UDP-glucuronosyltransferases.

  2004cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004cited by this paper
• Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity.

  2004cited by this paper
• Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.

  2003cited by this paper
• Novel Functional Polymorphisms in the UGT1A7 and UGT1A9 Glucuronidating Enzymes in Caucasian and African-American Subjects and Their Impact on the Metabolism of 7-Ethyl-10-hydroxycamptothecin and Flavopiridol Anticancer Drugs

  2003cited by this paper
• Expression and Characterization of Recombinant Human UDP-glucuronosyltransferases (UGTs)

  2003cited by this paper
• Comparative molecular field analysis of substrates for an aryl sulfotransferase based on catalytic mechanism and protein homology modeling.

  2002cited by this paper
• Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates.

  2002cited by this paper
• Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes.

  2002cited by this paper
• Structural and functional studies of UDP-glucuronosyltransferases.

  1999cited by this paper
• Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa.

  1999cited by this paper
• Comparative protein modelling by satisfaction of spatial restraints.

  1993cited by this paper
• Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.

  1988cited by this paper

• In Silico ADME Methods Used in the Evaluation of Natural Products

  2025cites this paper
• Insight into the structure, oligomerization, and the role in drug resistance of human UDP-glucuronosyltransferases

  2025cites this paper
• Molecular modeling approaches to address drug-metabolizing enzymes (DMEs) mediated chemoresistance: a review

  2021cites this paper
• Discovery of Hydroxyamidine Based Inhibitors of IDO1 for Cancer Immunotherapy with Reduced Potential for Glucuronidation.

  2020cites this paper
• Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronosyltransferase Enzymes.

  2019influential citation
• A model of acquired resistance to the novel AR-NTD inhibitor ralaniten reveals resistance occurs via a selective metabolism pathway

  2018cites this paper
• Structure and Protein–Protein Interactions of Human UDP-Glucuronosyltransferases

  2016cites this paper
• Roles of UGT, P450, and Gut Microbiota in the Metabolism of Epacadostat in Humans

  2016cites this paper
• Wedelolactone metabolism in rats through regioselective glucuronidation catalyzed by uridine diphosphate-glucuronosyltransferases 1As (UGT1As).

  2016cites this paper
• Un nouveau variant rare entrainant la modification post-traductionnelle de l'enzyme UGT2B7 et affectant son activité

  2016cites this paper
• The Role of UGT, CYP and Gut Microbiota in the Metabolism of Epacadostat (EPA) in Humans

  2016cites this paper
• Flavonoid interactions during digestion, absorption, distribution and metabolism: a sequential structure–activity/property relationship-based approach in the study of bioavailability and bioactivity

  2015cites this paper
• Regio- and isoform-specific glucuronidation of psoralidin: evaluation of 3-o-glucuronidation as a functional marker for UGT1A9.

  2015cites this paper
• C-8 Mannich base derivatives of baicalein display improved glucuronidation stability: exploring the mechanism by experimentation and theoretical calculations

  2015cites this paper
• SVM Classification and CoMSIA Modeling of UGT1A6 Interacting Molecules

  2014cites this paper
• Absolute quantification of UGT1A1 in various tissues and cell lines using isotope label-free UPLC-MS/MS method determines its turnover number and correlates with its glucuronidation activities.

  2014cites this paper
• Toward the production of flavone-7-O-β-d-glucopyranosides using Arabidopsis glycosyltransferase in Escherichia coli

  2013cites this paper
• Revolving door action of breast cancer resistance protein (BCRP) facilitates or controls the efflux of flavone glucuronides from UGT1A9-overexpressing HeLa cells.

  2013cites this paper
• Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes

  2012cites this paper